Clinical trial · no report yet · Phase 3
SunRISe-5
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
- NCT06211764 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 45 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 29 | |
| Podcasts | 13 | |
| X threads | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- 17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-200; Mitomycin C; Gemcitabine
- Arms
- Group A: TAR-200 · Experimental
- Group B: Mitomycin C (MMC) or Gemcitabine · Active comparator
- Enrollment
- 272
- Primary outcomes
- Disease-free Survival (DFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Apr 9, 2024
- Primary completion
- Nov 27, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06211764 · updated Sep 25, 2026